Solutions

Online Inquiry

CAR-T In Vitro Efficacy Services with OncoSolid™ Mesothelioma Organoid Models

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Mesothelioma Organoid Models

Mesothelioma (MM) is commonly derived from mesothelium tissue of the lung and chest wall after exposure to crisis asbestos. Malignant mesothelioma is of low incidence, but heterogeneous and aggressive cancer. There is limited clinical treatment for MM with minimal effects. A sound preclinical model is critical to understand tumor biology and developing new therapeutic strategies. An organoid model is a 3D cell culture system that stands between 2D cell lines and in vivo animal models. Cancer organoids recapitulate the major alterations in molecular that mediate tumor cell resistance to clinical treatment. Furthermore, different types of cell components of tumors can be retained or introduced to organoid models to partially reproduce tumor microenvironment and hinder therapeutic drugs and cell migration. Cancer organoids are a popular preclinical tool for potential immunotherapy development and assessment.

Mesothelioma Organoid Establishment and Application Service at Creative Biolabs

Creative Biolabs provides a panel of well-characterized Malignant mesothelioma cancer organoid models that mirror the mutation characters and heterogeneity of human tumor tissues to predict the responses of CAR-based cell therapies.

Workflow

Fig.1 Schematic illustration of the main steps for mesothelioma cancer organoids production from mouse tumor tissue. (Gao, et al., 2022)

Subtypes of Organoids in Our Organoid Biobank

Normal Organoid

Normal pleura organoids
iPSCs differentiated organoids
Animal derived normal organoids

Cancer Organoid

Patient-derived cancer organoids
Genetically engineered mouse derived cancer organoids

Histological Subtypes

Epithelioid
Sarcomatoid
Biphasic

Complete Characterization of Colorectal Cancer Organoids

Advanced multi-omics techniques and accurate histopathological methods are used to analyze human patients' tissues and various pathway-derived cancer organoids.

Molecular Characterization

Category

Genetic Characterization
Chromosomic Characterization
Epigenetic Characterization

Techniques

Next generation sequencing (NGS)
Comparative genomic hybridization (CGH) Single nucleotide polymorphism (SNP
Karyotyping analyses
Next generation sequencing (NGS)
Proteomic Analysis
Epigenomics

Function

Single nucleotide variants
Gene mutation landscape
Copy number changes
Gene fusions and splicing alterations
Epigenomic landscape
Chromosomal rearrangements

Histomorphology

Immunohistochemistry
RT-PCR
microscopy imaging
ELISA

Live/dead staining
Nuclei staining
Biomarker staining

Stem cell identification
Tumor identification
Morphology
Size
Histological organization

Highlights

Multiple passages and the long-term culture of organoids
Screen therapeutic molecules in a high-throughput type
Optimal culture medium to support organoids and T cell growth
Validated highly efficient organoids generation protocol
Reliable and reproducible experiment data

CAR-T Efficacy Test

The advanced preclinical cancer organoid models are useful to test the anti-tumor activity of promising immunotherapies in vitro.

CAR-T and mock T cells are co-cultured with cancer organoids.
Cancer organoids and T cells can be engineered or labeled with a fluorescent protein to facilitate observation by imaging.
The organoid responses and T cell activities can both be monitored for evaluation.

CAR-T Efficacy Test

Applications

Study the pathogenesis of cancer

Cellular and molecular features of mesothelioma cancer.
Microenvironment influence.
Epithelial cell to mesenchymal cell transition in tumor formation.

Serve as a preclinical model

Serve as a preclinical model to development now therapeutics, various anti-tumor molecules and cells.

Gene editing

Genetically editing cancer organoids using CRISPR/Cas9. .
Identify originate of oncogenes and discover new strategies for treatment.

Fig.2 Malignant mesothelioma cancer organoids are a useful tool for preclinical studies. (Gao, et al., 2022)

Related CAR-T Products and Services at Creative Biolabs

Creative Biolabs is committed to CAR-T therapy development using various advanced techniques and strategies. We have a library of CAR-cell therapy-related products that could be used for CAR-T production and efficacy test to get more information on lateral clinical responses.

If you're interested in our services, please contact us for a further consultant.

References

Guerra, E.; et al. Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics. Int. J. Mol. Sci. 2022, 23: 405.
Gao, Y.; et al. Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today? Cancers. 2022, 14: 3758.